Klara A. Dickinson, Senior Vice President, Regulatory Affairs and Compliance, was previously Vice President of Regulatory Affairs and Healthcare Compliance Officer at CoTherix, Inc. In this role, Ms. Dickinson led the filing of the NDA and label negotiations for the company's initial product, Ventavis(R) (iloprost) Inhalation Solution, an orphan drug. Prior to CoTherix, Ms. Dickinson was at Scios, Inc. as Associate Director of Regulatory Affairs where she was instrumental in securing regulatory approval for Natrecor(R) (nesiritide). From 1993 to 1997, she held several positions in the Quality Control and Regulatory Affairs departments at DEY Laboratories.
Kevin D. Weber, Senior Vice President Global Strategy and Operations, joined Hyperion Therapeutics from Ucyclyd Pharma, Inc, a subsidiary of Medicis Pharmaceuticals Corporation, where he was Vice President, General Manager. Mr. Weber's 22 years of pharmaceutical experience includes management positions with Rhone-Poulenc Rorer, VHA and Medicis Pharmaceuticals. He has successfully launched and managed several pharmaceutical brands in a variety of therapeutic areas including gastrointestinal (Maalox(R)), dermatology (Dynacin(R)), respiratory (Azmacort(R), Intal(R), and Orapred(R)) and rare metabolic disorders (AMMONUL and BUPHENYL(R) (sodium phenylbutyrate)).
Wayne B. Davis, PhD, MBA, Vice President, Clinical Operations joins
Hyperion from SuperGen, Inc. where he most recently served as Senior Vice
President, Clinical Research. During his tenure, Dr. Davis led the project
team for SuperGen's first targeted anti-cancer therapeutic, MP470,
resulting in the IND filing in March, 2007 and the initial enrollment of
the first-in- human clinical study in July. Prior to SuperGen, Dr. Davis
served as Vice President, Operations at PRA International, Executive Vice
President Global Operational Services and Director General, North America
at CroMedica, Inc. and Vi
|SOURCE Hyperion Therapeutics, Inc.|
Copyright©2007 PR Newswire.
All rights reserved